Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.

Slides:



Advertisements
Similar presentations
Con: Asymptomatic Ulcerative Colitis Patients on an Immunomodulator with Persistent Moderate Mucosal Inflammation Should Not Add A Biologic or Switch to.
Advertisements

Miguel Regueiro, M.D. Professor of Medicine
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Peter R. McNally, DO, FACP, FACG Lone Tree, Colorado
Journal Club: Biologic Agents in UC, Systematic Review and Network Meta-analysis, by Danese et al., Annals 2014 Barrett G. Levesque, MD Assistant Professor.
Thomas Ullman, M.D. Chief Medical Officer
Colitis in the Very Young
A patient with severe Crohn's disease, an ileal stricture and proximal dilation on CTE should have medical therapy first Uma Mahadevan MD Professor of.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
What do we do when the patient loses their response to an anti-TNF: Minor tweaks or major treatment changes? Robert N. Baldassano, MD Colman Professor.
End points in IBD treatment Mucosal healing Vs Symptom relief Jose Francis Lakeshore Hospital Kochi.
Dr. Drelichman Surgical Techniques Part 2. Crohn’s Disease Laparoscopic Colectomy - Results: Patient Outcomes Conversion Rate 5.9%
How Should We be Assessing and Documenting Endoscopies in IBD: Incorporating Standard Scoring Systems into Patient Care Gary R Lichtenstein, MD Director,
FMT Trial Design: How Do We Design Meaningful Studies in Inflammatory Bowel Disease? Alan C. Moss MD, FEBG, FACG, AGAF Associate Professor of Medicine.
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
Ghassan Wahbeh MD Associate Professor, Director IBD Program Seattle Children’s Hospital University of Washington.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Q UALITY R EPORTING F OR C OLONOSCOPY I N IBD Gil Y. Melmed, MD, MS Cedars-Sinai Medical Center CCFA Advances in IBD Orlando, FL December 2014.
Prevention of Postoperative Crohn’s disease
Joel R. Rosh, MD Director, Pediatric Gastroenterology
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Colonoscopic surveillance for prevention of colorectal cancer in people with ulcerative colitis, Crohn’s disease or adenomas NICE CG March 2011.
Colonoscopy; Surveillance Indications
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
William J. Sandborn, MD Chief, Division of Gastroenterology
COMPARING YIELD AND COST OF FOBT AND FS IN AN AVERAGE RISK POPULATION: RESULTS AFTER 2 SCREENING ROUNDS N.Segnan MD, Ms Epi Center for Cancer Prevention.
Controversies and challenges in the clinical care of patients with IBD: You can’t always get what you want! Stephen B. Hanauer, MD University of Chicago.
“Antibiotics and corticosteroids: Indications and approaches”
Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.
Vedolizumab in Pediatric IBD: We are Ready to Use It
1 Top-Down vs Step-Up Trial Endoscopic Substudy: Mucosal Healing Patients, % P
The only end-points of therapy that matter are mucosal healing, normal blood work, and negative radiologic studies. Robert N. Baldassano, MD Colman Family.
Brian Cox Research Associate Professor: Cancer epidemiology and screening University of Otago Hugh Adam Cancer Epidemiology Unit Department of Preventive.
IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.
The Un-CV. Results We were unable to identify any randomised controlled trials of parachute intervention. Conclusions As with many interventions intended.
You Can Never Stop a Biologic
Should we change how we position biologics in ulcerative colitis? Bruce E. Sands, MD, MS Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.
Time to initial resolution of rectal bleeding and high stool frequency in patients who achieved clinical and endoscopic remission after up to 8 weeks.
Sustaining Quality. “Expectations will always exceed capacity. The service must always be changing, growing and improving…”. Aneurin Bevan, 1948.
(A) Surveillance colonoscopies for detecting dysplasia and preventing colorectal carcinoma. (B) Management of visible lesions at endoscopy. A visible lesion.
William J. Sandborn, M.D., Brian G. Feagan, M.D., Paul Rutgeerts, M.D., Ph.D., Stephen Hanauer, M.D., Jean-Frederic Colombel, M.D., Bruce E. Sands, M.D.,
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis SANDRO ARDIZZONE,* ANDREA CASSINOTTI,*
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
High frequency of early colorectal cancer in inflammatory bowel disease M W M D Lutgens, F P Vleggaar, M E I Schipper, P C F Stokkers, C J van der Woude,
GASTROENTEROLOGY 2008; 134 :688–695 소화기내과 R4 이 재 연.
N Engl J Med 2012;367: Dae youn.kim/Prof.Chang hyun Lee.
Cumulative Probability of Developing Colon Cancer in UC Patients
Seeking Treatments for PSC Out of the Desert and into the Woods
Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.
CASE DISCUSSION: Crohn's disease patient with bad perianal disease- are new therapies any help? Alana Wichmann, APN, MSN, FNP, Advanced Practice Nurse,
Optimizing Use of Biological Agents in Ulcerative Colitis
Volume 135, Issue 4, Pages (October 2008)
Pathways in Managing Ulcerative Colitis
Managing IBD.
Raymond Cross, MD, MS, AGAF Associate Professor of Medicine
Illustrations in Ulcerative Colitis
Critical Appraisal & Literature review
Optimizing Outcomes in Crohn Disease
Methotrexate for Ulcerative Colitis: To Use or Not to Use?
Volume 146, Issue 1, Pages e1 (January 2014)
Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study  William J. Sandborn, William F. Stenson,
The efficacy and safety of omalizumab in pediatric allergic asthma
Endoscopic Assessment and Treating to Target Increase the Likelihood of Mucosal Healing in Patients With Crohn’s Disease  Guillaume Bouguen, Barrett G.
Presentation data from US VICTORY Consortium
Presentation data from US VICTORY Consortium
Infliximab trough levels above 7 μg/mL in inflammatory bowel disease treated with infliximab: Better control of inflammation without increased risk of.
Crohn’s Disease Biologic Pathway
Critical Appraisal & Literature review
Slides compiled by Dr. Najma Ahmed
Presentation transcript:

Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Director, UCSD IBD Center

Arguments for treating to target in ulcerative colitis It is feasibleIt is feasible It is associated with a reduced rate of colectomy and an increased rate of steroid-free remissionIt is associated with a reduced rate of colectomy and an increased rate of steroid-free remission It is associated with a reduced rate of colorectal dysplasia and cancerIt is associated with a reduced rate of colorectal dysplasia and cancer It is logical and obviously the right thing to doIt is logical and obviously the right thing to do

It is feasible: Treating to target in ulcerative colitis

Treat-to-Target Algorithm Bouguen G, Levesque BG, Sandborn WJ. Clin Gastroenterol Hepatol (In Press) ) CRP, C-reactive protein.

Study population STUDY POPULATION UCSD IBD Center Only one endoscopy At least 2 consecutive assessments No inflammation at baselineI NFLAMMATION AT BASELINE No endoscopy 144 patients 31 patients 53 patients 60 patients 15 patients 45 patients Bougen G, Levesque B, Sandborn W. Inflam Bowel Dis 2014 (In Press)

Endoscopic procedures 159 endoscopic procedures159 endoscopic procedures 92 colonoscopy 67 flexible sigmoidoscopy 60 patients had at least 2 consecutive endoscopic procedures60 patients had at least 2 consecutive endoscopic procedures 26 patients (43%): 3 consecutive procedures26 patients (43%): 3 consecutive procedures 8 patients (13%): 4 consecutive procedures8 patients (13%): 4 consecutive procedures 2 patients (3%): 5 consecutive procedures2 patients (3%): 5 consecutive procedures median follow-up of 76 weeks (IQR ) Endoscopy 1 Endoscopy 2 Endoscopy 3 Endoscopy 4 Median time 19 weeks Median time 19 weeks Median time 20 weeks Median time 20 weeks Median time 17 weeks Median time 17 weeks Bougen G, Levesque B, Sandborn W. Inflam Bowel Dis 2014 (In Press)

Adjustment in medical therapy and surgery Overall cohort :Overall cohort : 5-ASA introduction: 2 events 5-ASA increase dose: 6 events Oral steroids introduction: 11 events Anti-TNF Introduction: 20 events Anti-TNF Optimization/switch: 11 events Immunosuppression introduction: 18 patients Surgery: 7 patientsSurgery: 7 patients MEDIAN FOLLOW-UP = 76 weeks (IQR ) MEDIAN TIME BETWEEN PROCEDURE = 25 weeks (16-42) Bougen G, Levesque B, Sandborn W. Inflam Bowel Dis 2014 (In Press)

Cumulative probability of reaching mucosal healing and histologic healing Bougen G, Levesque B, Sandborn W. Inflam Bowel Dis 2014 (In Press)

Reaching mucosal healing according to medical management during follow up multivariate analysis: adjustments in medical therapy Bougen G, Levesque B, Sandborn W. Inflam Bowel Dis 2014 (In Press)

It is associated with a reduced rate of colectomy and an increased rate of steroid-free remission

Mucosal Healing after treatment as predictor of subsequent disease course in ulcerative colitis Frøslie KF, et al. Gastroenterology. 2007;133: Pts with MH at 1 year Pts without MH at 1 year p=0.02

Mucosal Healing and Time to Colectomy in Infliximab- treated Patients: Endoscopy Subscore 1 = MILD2 = MODERATE3 = SEVERE0 = NORMAL Colombel JF, Sandborn WJ, et al. Gastroenterology 2011;141:

Association Between Week 8 Mayo Endoscopy Sub- score and and Corticosteroid-Free Symptomatic Remission at Week 30 During Anti-TNF Antibody Therapy Week 8 Mayo endoscopy sub-score Corticosteroid-free symptomatic remission, % P value 046< Colombel JF, Sandborn WJ. Gastroenterology 2011

It is associated with a reduced rate of colorectal dysplasia and cancer

Rutter et al Gastroenterology 2004;126:451 OR=5.13 OR=2.54 P=0.001 P<0.001 Colonoscopy inflammation score Histological inflammation score Odds ratio for colorectal cancer (95% CI) OR for each 1 point increase in inflammatory score Predicting cancer risk in UC Disease extent PSC Disease duration Family history of CRC Disease extent PSC Disease duration Family history of CRC

It is logical and obviously the right thing to do

Parachute use to prevent death and major trauma related to gravitational challenge: a systematic review of randomized controlled trials Objectives: To determine whether parachutes are effective in preventing major trauma related to gravitational challenge Design: Systematic review of randomized controlled trials Data sources: Medline, Web of Science, Embase, and the Cochrane Library databases; appropriate internet sites and citation lists Study selection: Studies showing the effects of using a parachute during free fall Main outcome measure: Death or major trauma, defined as an injury severity score > 15 Gordon CS. BMJ 2003

Parachute use to prevent death and major trauma related to gravitational challenge: a systematic review of randomized controlled trials Results: We were unable to identify any randomized controlled trials of parachute intervention Conclusions: As with many interventions intended to prevent ill health, the effectiveness of parachutes has not been subjected to rigorous evaluation by using randomized controlled trials. Advocates of evidence based medicine have criticized the adoption of interventions evaluated by using only observational data. We think that everyone might benefit if the most radical protagonists of evidence based medicine organized and participated in a double blind, randomized, placebo controlled, crossover trial of the parachute Gordon CS. BMJ 2003

It is logical and obviously the right thing to do You don’t need a randomized controlled trial to determine that using a parachute is the right thing to doYou don’t need a randomized controlled trial to determine that using a parachute is the right thing to do Do you need a randomized controlled trial to determine that healing the colon is the right thing to do?Do you need a randomized controlled trial to determine that healing the colon is the right thing to do?

Treating to Mucosal Healing in Ulcerative Colitis It is feasibleIt is feasible It is associated with a reduced rate of colectomy and an increased rate of steroid- free remissionIt is associated with a reduced rate of colectomy and an increased rate of steroid- free remission It is associated with a reduced rate of colorectal dysplasia and cancerIt is associated with a reduced rate of colorectal dysplasia and cancer It is logical and obviously the right thing to doIt is logical and obviously the right thing to do